Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients

Bavbek, Sevim; Ataman, Şebnem; Akıncı, Ayşen; Castells, Mariana

doi:10.1016/j.jaip.2015.01.009

Cited by 39 publications

(31 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More recently, the same authors reported 12 patients with local and systemic hypersensitivity reaction to etanercept and adalimumab, successfully desensitized using a similar protocol. 9 To our knowledge, this is the first report of a successful rapid desensitization to anakinra in a case of delayed-type lichenoid reaction, suggesting that this procedure could be effective in either acute or delayed-type hypersensitivity.…”

mentioning

confidence: 74%

Successful rapid subcutaneous desensitization to anakinra in a case of delayed‐type hypersensitivity reaction

et al. 2016

View full text Add to dashboard Cite

Z et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med 2012; 4:126ra34. 6 Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg 2010; 36:1361-71. 7 Glaser DA, Hossain P, Perkins W et al. Long-term safety and efficacy of bimatoprost solution 0Á03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial. Br J Dermatol 2015; 172:1384-94. 8 Champagne C, Taylor M, Farrant P. Permanent chemotherapyinduced nonscarring alopecia and premature ovarian failure. Clin Exp Dermatol 2015; 40:589-90.Funding sources: none.Conflicts of interest: none declared.

show abstract

mentioning

confidence: 74%

Successful rapid subcutaneous desensitization to anakinra in a case of delayed‐type hypersensitivity reaction

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Desensitization to drugs used in rheumatology such as TNF blockers , rituximab [8,15,18,19,[30][31][32][33][34][35][36][37][38][39][40][41][42], tocilizumab [43][44][45][46][47][48], IL-17 blockers (ixekizumab) [49] and anti-IL-1 (anakinra) [50][51][52][53] has been described. Most of the described procedures were performed in patients with rheumatoid arthritis [8,32] but desensitization in patients with lupus or spondyloarthropathies [24], adult-onset Still disease [43], IgG4-related disease [40] and autoinflammatory disorders [51][52][53] has also been performed with success. In most of the published cases desensitization was performed in patients with immediate reactions, but single reports on successful desensitization in delayed reactions [47] and serum sickness disease (type III reaction) [34] have been published as well.…”

Section: Medical Indicationsmentioning

confidence: 99%

“…As some of the biologicals are administered via the subcutaneous route, case series of subcutaneous desensitization have been described as well [9,10,24]. According to the protocol proposed by Bavbek et al [24] wadalimumab was administered every 30 minutes; the initial dose was 0.5 mg, followed by 0.75 mg, 1.25 mg, No data on golimumab and certolizumab desensitization was present.…”

Section: Rapid Subcutaneous Protocols Of Desensitizationmentioning

confidence: 99%

Desensitization to biological agents used in rheumatology

Makowska

Lewandowska–Polak

2020

Reumatologia

View full text Add to dashboard Cite

Biological agents such as monoclonal antibodies and fusion proteins are widely used for the treatment of patients with various rheumatic disorders, influencing the quality of life, disability and even mortality in patients. However, biological agents can evoke adverse reactions of different grades of severity. Although drug avoidance remains a gold standard in the care of patients hypersensitive to medication, in certain clinical situations the culprit drug is the drug of choice and cannot be replaced by another equally effective compound. In such cases, desensitization can allow the patient to be treated within current guidelines and with the most effective treatment. The authors searched Medline and Scopus databases for English-language sources using the following key words: hypersensitivity, desensitization, biologicals, adalimumab, etanercept, adalimumab, certolizumab, golimumab, rituximab, infliximab, ixekizumab, tocilizumab, anakinra and canakinumab. The aim of our review is to present the current knowledge about desensitization to biological agents and some guidelines according to patient inclusion, contraindications, procedures, and safety requirements. Drug desensitization is a new issue in rheumatology, and the solution to the problem of allergic reactions to biological drugs, which gives patients with rheumatic diseases the opportunity to extend and prolong their therapy. The present article is one of the first widely discussing this topic in the biological treatment of rheumatic diseases.

show abstract

“…It enables the patient to receive the full treatment dose while protecting from anaphylaxis [7••]. Type I DHR to monoclonals are subject to RDD, and immediate injection-site and systemic reactions elicited by subcutaneous agents (such as adalimumab and etanercept) have also had successful desensitization protocols established (Table 6-desensitization to adalimumab) [47].…”

Section: Desensitization To Monoclonal Antibodiesmentioning

confidence: 99%